Early Response to Everolimus Therapy Detected on Ga-68-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor

ÖZKAN E., SOYDAL Ç., Semirgin S. U., Yapici O., ATMACA A., Demirag G.

CLINICAL NUCLEAR MEDICINE, vol.41, no.7, pp.561-563, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 41 Issue: 7
  • Publication Date: 2016
  • Doi Number: 10.1097/rlu.0000000000001242
  • Journal Name: CLINICAL NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.561-563
  • Keywords: Ga-68-DOTATATE PET/CT, everolimus, treatment response, RADIONUCLIDE THERAPY
  • Ankara University Affiliated: Yes

Abstract

Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-68-DOTATATE PET/CT.